Astrana Health (NASDAQ:ASTH – Get Free Report) was upgraded by Baird R W to a “strong-buy” rating in a research report issued to clients and investors on Thursday, Zacks.com reports. ASTH has been the topic of several other reports. Truist Financial upped their target price on Astrana Health from $41.00 to $44.00 and gave the […]